NACUITY PHARMACEUTICALS

nacuity-pharmaceuticals-logo

Nacuity Pharmaceuticals is a pharmaceutical company that aims to develop a breakthrough treatment for retinitis pigmentosa (“RP”) and potentially other ophthalmological indications. Nacuity has assembled an accomplished team and has received significant financial and technical support from the Foundation Fighting Blindness (FFB). FFB aims to drive research providing prevention, treatments and cures for people affected by blinding retinal diseases. FFB has invested nearly $700 million in this effort Over the last 46 years. FFB is a significant supporter of Dr. Campochiaro’s research and has committed to fund a substantial portion of Nacuity’s Phase 1 and Phase 2 trials through a milestone-based matching program grant to Nacuity in support of our NPI-001 development program.

#SimilarOrganizations #People #Financial #Website #More

NACUITY PHARMACEUTICALS

Social Links:

Industry:
Health Care Pharmaceutical

Founded:
2016-01-01

Address:
Fort Worth, Texas, United States

Country:
United States

Website Url:
http://www.nacuity.com

Total Employee:
11+

Status:
Active

Contact:
817-336-3000

Total Funding:
18.47 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics


Similar Organizations

novabay-pharmaceuticals-logo

NovaBay Pharmaceuticals

NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.

scilex-pharmaceuticals-logo

Scilex Pharmaceuticals

Scilex Pharmaceuticals is an emerging pharmaceutical company focused on acquiring and commercializing late-stage prescription products.


Current Advisors List

sanford-hillsberg_image

Sanford Hillsberg Chairman @ Nacuity Pharmaceuticals
Board_member

halden-conner_image

Halden Conner Board Director @ Nacuity Pharmaceuticals
Board_member

benjamin-yerxa_image

Benjamin Yerxa Board Member @ Nacuity Pharmaceuticals
Board_member
2019-10-01

not_available_image

David Wohlberg Board Director @ Nacuity Pharmaceuticals
Board_member

not_available_image

Isaac Blech Vice-Chairman of Board @ Nacuity Pharmaceuticals
Board_member

Current Employees Featured

halden-conner_image

Halden Conner
Halden Conner CEO & President @ Nacuity Pharmaceuticals
CEO & President
2016-05-01

Founder


not_available_image

David Wohlberg

halden-conner_image

Halden Conner

not_available_image

Isaac Blech

sanford-hillsberg_image

Sanford Hillsberg

Investors List

foundation-fighting-blindness_image

Foundation Fighting Blindness

Foundation Fighting Blindness investment in Series B - Nacuity Pharmaceuticals

retinal-degeneration-fund_image

Retinal Degeneration Fund

Retinal Degeneration Fund investment in Series B - Nacuity Pharmaceuticals

maxim-group_image

Maxim Group

Maxim Group investment in Series B - Nacuity Pharmaceuticals

hugo-peris_image

Hugo Peris

Hugo Peris investment in Series A - Nacuity Pharmaceuticals

Official Site Inspections

http://www.nacuity.com Semrush global rank: 5.82 M Semrush visits lastest month: 1.43 K

  • Host name: 138.40.180.107.host.secureserver.net
  • IP address: 107.180.40.138
  • Location: Scottsdale United States
  • Latitude: 33.6013
  • Longitude: -111.8867
  • Metro Code: 753
  • Timezone: America/Phoenix
  • Postal: 85260

Loading ...

More informations about "Nacuity Pharmaceuticals"

Home – Nacuity Pharmaceuticals

Developing powerful, targeted, prescription therapies to stop oxidative tissue damage. Addressing oxidative stress, a driver of blinding eye diseases and a broad spectrum of serious chronic …See details»

About Us - Nacuity Pharmaceuticals

Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. The company’s powerful, targeted therapies aim to stop oxidative tissue damage, a driver of blinding eye diseases and a broad …See details»

Our Science - Nacuity Pharmaceuticals

Nacuity is the leader in innovative treatments for oxidative stress, the widely known, unaddressed disease mechanism hiding in plain sight. Oxidative stress has been implicated as a driver of blinding eye diseases and a broad …See details»

Nacuity Pharmaceuticals - Crunchbase Company …

Nacuity Pharmaceuticals is a pharmaceutical company that aims to develop a breakthrough treatment for retinitis pigmentosa. View contacts for Nacuity Pharmaceuticals to access new leads and connect with decision-makers.See details»

Nacuity Pharmaceuticals, Inc. - LinkedIn

Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. The company’s powerful, targeted therapies aim to stop oxidative tissue damage, a driver of...See details»

Nacuity Pharmaceuticals Announces $16.5 Million Series B …

FORT WORTH, TX - June 15, 2022 - Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and …See details»

Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 ...

Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. The company’s powerful, targeted therapies aim to stop oxidative tissue damage, a driver of …See details»

Nacuity Pharmaceuticals Announces $16.5 Million Series B

FORT WORTH, Texas, June 15, 2022 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, …See details»

Nacuity Pharmaceuticals Announces $16.5 Million Series B …

Jun 15, 2022 · Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. The company’s powerful, targeted therapies aim to stop oxidative tissue …See details»

Foundation Investing in Drug to Slow Many Forms of RP

Jan 19, 2017 · Nacuity Pharmaceuticals, Inc., a start-up company in Fort Worth, Texas, owns the rights to NACA for ophthalmology and will be developing the drug with support from FFB-CRI. …See details»

Nacuity Pharmaceuticals - Funding, Financials, Valuation & Investors

Nacuity Pharmaceuticals is a pharmaceutical company that aims to develop a breakthrough treatment for retinitis pigmentosa.See details»

Nacuity Pharmaceuticals Expands Board of Directors with …

Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. The company’s powerful, targeted therapies aim to stop oxidative tissue damage, a driver of …See details»

Nacuity Pharmaceuticals announces $16.5 million Series B financing

Jun 19, 2022 · Nacuity Pharmaceuticals Inc. this week announced the closing of a $16.5 million Series B financing led by Foundation Fighting Blindness and its venture arm RD Fund. …See details»

Nacuity Pharmaceuticals Announces First Patients Implanted in …

FORT WORTH, Texas, April 30, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, …See details»

Nacuity Pharmaceuticals Expands Board of Directors with

Nov 8, 2022 · Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. The company’s powerful, targeted therapies aim to stop oxidative tissue …See details»

Nacuity Pharmaceuticals - Contacts, Employees, Board Members, …

Nacuity Pharmaceuticals is a pharmaceutical company that aims to develop a breakthrough treatment for retinitis pigmentosa.See details»

Nacuity Pharmaceuticals - Overview, News & Similar companies

Nov 7, 2022 · View Nacuity Pharmaceuticals (www.nacuity.com) location in Texas, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»

Nacuity Pharmaceuticals Appoints Robert R. Ruffolo, Ph.D.,

FORT WORTH, Texas, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, …See details»

Nacuity’s Emerging Anti-Oxidative Therapy Moves into Clinical Trial

May 21, 2020 · Fort Worth-based Nacuity Pharmaceuticals is launching a Phase 1/2 clinical trial in Australia for NPI-001, an oral treatment designed to slow vision loss in people with retinitis …See details»

N acetylcysteine amide - Nacuity Pharmaceuticals - AdisInsight

May 28, 2024 · If your organization or you do not have a subscription, try one of the following: Contacting your organization’s admin about adding this content to your AdisInsight …See details»

linkstock.net © 2022. All rights reserved